Driehaus Capital ICLR Position
Exited3-Fund ConvergenceDriehaus Capital exited their position in ICON Plc (ICLR) in Q3 2024, after holding the stock for 3 quarters.
The position was first reported in Q1 2024 and has been tracked across 3 quarterly 13F filings.
ICLR is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
About ICON Plc
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Full company profile →Short Interest
2.7%
0.9 days to cover
Driehaus Capital ICLR Position History
Frequently Asked Questions
Does Driehaus Capital own ICLR?
No. Driehaus Capital exited their position in ICON Plc (ICLR) in Q3 2024. They previously held the stock for 3 quarters.
How many hedge funds own ICLR?
3 specialist biotech hedge funds currently hold ICLR, including OrbiMed Advisors, Perceptive Advisors, Redmile Group. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Driehaus Capital first buy ICLR?
Driehaus Capital's position in ICLR was first reported in Q1 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Driehaus Capital's ICLR position increasing or decreasing?
Driehaus Capital completely exited their ICLR position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ICLRCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Driehaus CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →